이근석 교수
#유방암의 항암화학요법
|
학력
1985-03~1991-02 서울대학교 의과대학 의학과 대졸(의대)
1993-03~1995-02 서울대학교 대학원 의학과 대학원졸(석사)
2001-03~2011-02 서울대학교 대학원 의학과 대학원졸(박사)
1993-03~1995-02 서울대학교 대학원 의학과 대학원졸(석사)
2001-03~2011-02 서울대학교 대학원 의학과 대학원졸(박사)
경력
1991-03~1992-02 서울대병원 인턴
1992-03~1996-02 서울대병원 전공의
1996-05~1999-04 군복무
1999-05~2000-02 서울대병원 전임의
2000-03~2001-02 인제대 일산백병원 전임강사
2001-03~2004-12 한림대 강동성심병원 조교수
2005-01~현재 국립암센터 유방암센터 의사직
2006-03~2009-11 국립암센터 대장암센터 전문의
2008-04~2009-01 국립암센터 임상시험센터 임상시험센터장
2009-02~2019-01 국립암센터 임상시험센터 전문의
2010-10~2011-12 국립암센터 외래주사치료실 실장
2014-10~현재 국립암센터 유방암센터 센터장
2019-02~현재 국립암센터 임상시험센터 전문의
2019-02~현재 국립암센터 혈액종양내과분과
1992-03~1996-02 서울대병원 전공의
1996-05~1999-04 군복무
1999-05~2000-02 서울대병원 전임의
2000-03~2001-02 인제대 일산백병원 전임강사
2001-03~2004-12 한림대 강동성심병원 조교수
2005-01~현재 국립암센터 유방암센터 의사직
2006-03~2009-11 국립암센터 대장암센터 전문의
2008-04~2009-01 국립암센터 임상시험센터 임상시험센터장
2009-02~2019-01 국립암센터 임상시험센터 전문의
2010-10~2011-12 국립암센터 외래주사치료실 실장
2014-10~현재 국립암센터 유방암센터 센터장
2019-02~현재 국립암센터 임상시험센터 전문의
2019-02~현재 국립암센터 혈액종양내과분과
논문
2020 SCI-E A phase Ib study of alpelisib or buparlisib combined with tamoxifen plus goserelin in premenopausal women with HR-positive HER2-negative advanced breast cancer: CLINICAL CANCER RESEARCH. Online:Published (10.107)
2020 SCI-E Cumulative incidence of chemotherapy-induced cardiotoxicity during a 2-year follow-up period in breast cancer patients: BREAST CANCER RESEARCH AND TREATMENT. 182(2):333~343 (3.831)
2020 SCI-E Genome-wide association study of genetic variants related to anthracycline-induced cardiotoxicity in early breast cancer: CANCER SCIENCE. Online:Published (4.966)
2020 SCI-E Phase I and pharmacokinetic study of the vascular-disrupting agent CKD-516 (NOV120401) in patients with refractory solid tumors: PHARMACOLOGY RESEARCH & PERSPECTIVES. 8(2):e00568~ (2.052)
2019 SCI Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer: THE NEW ENGLAND JOURNAL OF MEDICINE. Online:Published (70.67)
2019 SCI A pilot study on intermittent every other days of 5-dose Filgrastim compared with single Pegfilgrastim in breast Cancer patients receiving adjuvant Docetaxel, doxorubicin, and cyclophosphamide (TAC) chemotherapy: INVESTIGATIONAL NEW DRUGS. Online:Published (2.663)
2019 SCI Genomic characteristics of triple-negative breast cancer nominate molecular subtypes that predict chemotherapy response: Molecular Cancer Research. Online:Published (4.484)
2019 SCI Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2 + metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16): British journal of cancer. Online:Published (5.416)
2019 SCI Anti-tumor activity of BET inhibitors in androgen-receptor-expressing triple-negative breast cancer.: SCIENTIFIC REPORTS. Online:Published (4.011)
2019 SCI-E Anti-tumor activity of BET inhibitors in androgen-receptor-expressing triple-negative breast cancer: SCIENTIFIC REPORTS. 9(1):13305~ (3.998)
2019 SCI Molecular alterations and poziotinib efficacy, a pan-HER inhibitor, in human epidermal growth factor receptor2 (HER2)-positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2-positive breast cancer patients: INTERNATIONAL JOURNAL OF CANCER. 145(6):1669~1678 (4.982)
2019 SCI-E Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor? Positive Metastatic Breast Cancer: JAMA ONCOLOGY. Online:Published (22.416)
2019 SCI Exploratory biomarker analysis from a phase II clinical trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine for HER2-negative metastatic breast cancer patients (KCSG BR13-11): BREAST CANCER RESEARCH AND TREATMENT. 178:367~377 (3.471)
2019 SCI The Sentinel Lymph Node Biopsy Using Indocyanine Green Fluorescence Plus Radioisotope Method Compared With the Radioisotope-Only Method for Breast Cancer Patients After Neoadjuvant Chemotherapy: A Prospective, Randomized, Open-Label, Single-Center Phase 2 Trial: ANNALS OF SURGICAL ONCOLOGY. 26(8):2409~2416 (3.681)
2019 SCI Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer: THE NEW ENGLAND JOURNAL OF MEDICINE. 381(4):307~316 (70.67)
2019 SCI-E Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11): Cancer Communications. 39(1):29~29 (0)
2019 SCI-E Integrative In Vivo Drug Testing Using Gene Expression Signature and Patient-Derived Xenografts from Treatment-Refractory HER2 Positive and Triple-Negative Subtypes of Breast Cancer: CANCERS. 11(4):E574~E574 (6.162)
2019 SCI A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients: British Journal of Cancer. 120(5):475~480 (5.416)
2019 SCI PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study: British Journal of Cancer. 120(2):172~182 (5.416)
2019 SCI-E randomized open label phase III tiral of irinotecan plus capecitabine versus capecitabine monotherapy in patients with metastatic breast cancer previously treated with anthracycline and taxane : PROCEED trial (KCSG BR 11-01): CANCER RESEARCH AND TREATMENT. 51(1):43~52 (3.363)
2018 SCI-E Predicting Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer: combined Statistical Modeling Using Clinicopathological Factors and FDG PET/CT Texture Parameters: clinical nuclear medicine. 44(1):21~29 (6.309)
2018 SCI A phase II trial of the pan-HER inhibitor poziotinib, in patients with HER2-positive metastatic breast cancer who had received at least two prior HER2-directed regimens: results of the NOV120101-203 trial: INTERNATIONAL JOURNAL OF CANCER. 143(12):3240~3247 (7.36)
2018 SCI-E Magnetic Resonance Imaging (MRI) Assessment of Residual Breast Cancer After Neoadjuvant Chemotherapy: Relevance to Tumor Subtypes and MRI Interpretation Threshold.: Clinical breast cancer. 18(6):459~467 (2.703)
2018 SCI Prognostic impact of skeletal muscle volume derived from crosssectional computed tomography images in breast cancer: BREAST CANCER RESEARCH AND TREATMENT. 172(2):425~436 (3.605)
2018 SCI Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer: EUROPEAN JOURNAL OF CANCER. 103:127~136 (7.191)
2018 SCI-E Oncologic Safety of Gonadotropin-Releasing Hormone Agonist for Ovarian Function Protection During Breast Cancer Chemotherapy: Clinical breast cancer. 18(5):e1165~e1172 (2.703)
2018 SCI Use of adjuvant chemotherapy in hormone receptor-positive breast cancer patients with or without the 21-gene expression assay: Breast cancer research and treatment. 170(1):69~76 (3.605)
2018 SCI-E Phase I/II clinical trial of everolimus combined with gemcitabine/cisplatin for metastatic triple-negative breast cancer.: Journal of Cancer. 9(7):1145~1151 (3.249)
2017 SCI-E Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial.: The Lancet. Oncology. 19(1):87~100 (33.9)
2017 SCI-E Quality of life on TSU-68: Combination of docetaxel and TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer previously treated with anthracycline.: Asia-Pacific journal of clinical oncology. 13(6):365~371 (1.959)
2017 SCI Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer.: European journal of cancer. 86:385~393 (6.029)
2017 SCI-E Prognostic Impact of Elective Supraclavicular Nodal Irradiation for Patients with N1 Breast Cancer after Lumpectomy and Anthracycline plus Taxane-based Chemotherapy (KROG 1418): A Multicenter Case-Controlled Study: Cancer Research and Treatment. 49(4):970~980 (3.772)
2017 SCI-E CKAP2 (cytoskeleton-associated protein2) is a new prognostic marker in HER2-negative luminal type breast cancer: PLOS ONE. 12(8):e0182107~e0182107 (2.806)
2017 SCI Characteristics of BRCA1/2 mutations carriers including large genomic rearrangements in high risk breast cancer patients: Breast Cancer Research and Treatment. 163(1):139~150 (3.626)
2017 SCI Efficacy and safety of everolimus in combination with trastuzumab and paclitaxel in Asian patients with HER2+ advanced breast cancer in BOLERO-1.: Breast cancer research. 19(1):47~47 (6.345)
2016 SCI-E Post-mastectomy Radiotherapy in Patients with pT1-2N1 Breast Cancer Treated with Taxane-based Chemotherapy: A Retrospective Multicenter Analysis (KROG 1418).: Cancer Research and Treatment. Online:Published (4.245)
2016 SCI-E Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results: Cancer Research and treatment. 49(2):423~429 (4.245)
2016 SCI-E Optimal radiation dose for patients with one to three lymph node positive breast cancer following breast-conserving surgery and anthracycline plus taxane-based chemotherapy: A retrospective multicenter analysis (KROG 1418): Oncotarget. 8(1):1796~1804 (5.008)
2016 SCI-E Accelerated whole breast irradiation in early breast cancer patients with adverse prognostic features.: Oncotarget. 7(49):81888~81898 (5.008)
2016 SSCI Three-Year Prospective Cohort Study of Factors Associated with Return to Work After Breast Cancer Diagnosis.: Journal of Occup Rehabilitation. Online:Published (1.644)
2016 SCI-E Effects of Postoperative Radiotherapy on Leptomeningeal Carcinomatosis or Dural Metastasis After Resection of Brain Metastases in Breast Cancer Patients: Cancer Research and Treatment. Online:Published (4.245)
2016 SCI-E The Significance of Serum HER2 Levels at Diagnosis on Intrinsic Subtype-Specific Outcome of Operable Breast Cancer Patients: PLOS ONE. 11(10):e0163370~e0163370 (3.057)
2016 SCI-E Locoregional Recurrence by Tumor Biology in Breast Cancer Patients after Preoperative Chemotherapy and Breast Conservation Treatment: Cancer research and treatment. 48(4):1363~1372 (4.245)
2016 SCI-E Prognostic Value of Axillary Nodal Ratio after Neoadjuvant Chemotherapy of Doxorubicin/Cyclophosphamide Followed by Docetaxel: A Multicenter Retrospective Cohort Study: Cancer Res Treatment. 48(4):1373~1381 (4.245)
2016 SCI-E An open label randomized parallel phase III trial evaluating the efficacy and safety of polymeric micelle formulated paclitaxel compared to conventional cremophor EL-based paclitaxel for recurrent or metastatic HER2 negative breast cancer: cancer research and treatment. Online:Published (4.245)
2016 SCI-E A Rare Case of Phyllodes Tumor Metastasis to the Stomach Presenting as Anemia: Cancer research and treatment. Online:Published (4.245)
2016 SCI A Comparative Study of Daily 3-Gy Hypofractionated and 1.8-Gy Conventional Breast Irradiation in Early-Stage Breast Cancer: Medicine. 95(19):e3320~e3320 (2.133)
2016 SCI Identifying the potential long-term survivors among breast cancer patients with distant metastasis: Annals of oncology. 27(5):828~833 (9.269)
2015 SCI-E Effect of Time Interval between Breast-conserving Surgery and Radiation Therapy on Outcomes of Node-positive Breast Cancer Patients Treated with Adjuvant Doxorubicin/Cyclophosphamide followed by Taxane: Cancer research and treatment. 48(2):483~490 (3.318)
2015 SCI-E Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer: Clinical Breast Cancer. 16(1):51~58 (2.107)
2015 SCI-E Impact of Molecular Subtype Conversion of Breast Cancers after Neoadjuvant Chemotherapy on Clinical Outcome: Cancer research and treatment. 48(1):133~141 (3.318)
2015 SSCI Changes in health-related quality of life and quality of care among terminally ill cancer patients and survival prediction: Multicenter prospective cohort study: Palliative & supportive care. 13(4):1103~1111 (1.525)
2015 SCI-E Breast Cancer-Related Lymphedema after Neoadjuvant Chemotherapy: Cancer research and treatment. 47(3):416~423 (3.318)
2015 SCI-E Effects of Second and Subsequent Lines of Chemotherapy for Metastatic Breast Cancer: Clinical breast cancer. 15(1):e55~e62 (2.107)
2014 SCI-E Outcomes of palliative weekly low-dose gemcitabine-Cisplatin chemotherapy in anthracycline- and taxane- pretreated metastatic breast cancer patients: Journal of breast cancer. 17(4):339~343 (1.317)
2014 SCI High Volumetric Breast Density Predicts Risk for Breast Cancer in Postmenopausal, but not Premenopausal, Korean Women: Annals of surgical oncology. 21(13):4124~4132 (3.943)
2014 SCI Identification and clinical implications of circulating microRNAs for estrogen receptor-positive breast cancer.: Tumor biology. 35(12):12173~12180 (2.84)
2014 SCI Treatment factors affecting breast cancer-related lymphedema after systemic chemotherapy and radiotherapy in stage II/III breast cancer patients: Breast cancer research and treatment. 148(1):91~98 (4.198)
2014 SCI Comparison of Sentinel Lymph Node Biopsy Guided by the Multimodal Method of Indocyanine Green Fluorescence, Radioisotope, and Blue Dye Versus the Radioisotope Method in Breast Cancer: A Randomized Controlled Trial: Annals of Surgical Oncology. 21(4):1254~1259 (3.943)
2014 SCI-E Association of Polymorphisms and Haplotypes in the Insulin-Like Growth Factor 1 Receptor (IGF1R) Gene with the Risk of Breast Cancer in Korean Women.: PLOS One. 9(1):e84532~e84532 (3.534)
2013 SCI Phase 2 trial of accelerated, hypofractionated whole-breast irradiation of 39 Gy in 13 fractions followed by a tumor bed boost sequentially delivering 9 Gy in 3 fractions in early-stage breast cancer: International Journal of Radiation Oncology Biology Physics. 87(5):1037~1042 (4.524)
2013 SCI-E Burdens, Needs and Satisfaction of Terminal Cancer Patients and their Caregivers: Asian Pacific Journal of Cancer Prevention. 14(1):209~216 (1.271)
2013 SCI Phase III, Multicenter, Randomized Trial of Maintenance Chemotherapy Versus Observation in Patients With Metastatistic Breast Cancer After Achieving Disease Control With Six Cycles of Gemcitabine Plus Paclitaxel As First-Line Chemotherapy: KCSG-BR07-02: Journal of Clinical Oncology. 31(4):1732~1739 (18.038)
2013 SCI Phase II study of irinotecan plus capecitabine in anthracycline- and taxane- pretreated patients with metastatic breast cancer: Investigational new drugs. 31(1):152~159 (3.498)
2013 SCI Effect of complementary and alternative medicine on the survival and health-related quality of life among terminally ill cancer patients: a prospective cohort study.: Annals of Oncology. 24(2):489~494 (7.384)
2013 SCI-E A Case of Locally Advanced Breast Cancer Complicated by Pulmonary Tumor Thrombotic Microangiopathy: Cancer Research and Treatment. 44(4):267~270 (0)
2012 SCI-E Percutaneous radiofrequency ablation for liver metastases in breast cancer patients: The Breast Journal. 19(5):563~565 (1.831)
2012 SCI-E Stage-to-stage Comparison of Neoadjuvant Chemotherapy Versus Adjuvant Chemotherapy in Pathological Lymph Node Positive Breast Cancer Patients: Japanese Journal of Clinical Oncology. 42(11):995~1001 (1.783)
2012 SCI Resumption or persistence of menstruation after cytotoxic chemotherapy is a prognostic factor for poor disease-free survival in premenopausal patients with early breast cancer: Annals of Oncology. 23(9):2283~2289 (6.425)
2012 SCI-E Efficacy of Exemestane after Nonsteroidal Aromatase Inhibitor Use in Metastatic Breast Cancer Patients: Asian Pacific journal of cancer prevention. 13(3):979~983 (0.659)
2012 SCI-E Correlation of HER2 p95HER2 and HER3 expression and treatment outcome of lapatinib plus capecitabine in her2-Positive Metastatic Breast Cancer: PLOS ONE. 7(7):e39943~e39943 (4.092)
2012 SCI Metaplastic breast cancer: clinicopathological features and its prognosis: Journal of clinical pathology. 65(5):441~446 (2.306)
2012 SCI Web-Based Tailored Education Program for Disease-Free Cancer Survivors With Cancer-Related Fatigue: A Randomized Controlled Trial: Journal of Clinical Oncology. 30(12):1296~1303 (18.372)
2012 SCI Phase II trial of preoperative paclitaxel, gemcitabine, and trastuzumab combination therapy in HER2 positive stage II/III breast cancer: The Korean Cancer Study Group BR 07-01: Breast Cancer Res Treat. 132(2):589~600 (4.431)
2012 SCI lack of any association between functionally significant CYP2D6 polymorphisms and clinical outcomes in early breast cancer patients receiving adjuvant tamoxifen treatment: Breast cancer research and treatment. 131(2):455~461 (4.431)
2012 SCI High serum TGF-a predicts poor response to lapatinib and capecitabine in HER2-positive breast cancer: Breast Cancer Research and Treatment. 125(1):107~114 (4.859)
2011 SCI A phase Ib study of preoperative lapatinib, paclitaxel, and gemcitabine combination therapy in women with HER2 positive early breast cancer: Investigational New Drugs. 30(5):1972~1977 (3.357)
2011 SCI Use of a Decision Aid to Help Caregivers Discuss Terminal Disease Status With a Family Member With Cancer: A Randomized Controlled Trial.: Journal of Clinical Oncology. 29(36):4811~4819 (18.97)
2011 SCI Locoregional recurrence of breast cancer in patients treated with breast conservation surgery and radiotherapy following neoadjuvant chemotherapy.: International Journal of Radiation Oncology*Biology*Physics. 81(5):e697~e705 (4.503)
2011 SCI Outcomes of Positron Emission Tomography-Staged Clinical N3 Breast Cancer Treated with Neoadjuvant Chemotherapy, Surgery, and Radiotherapy.: Int J Radiat Oncol Biol Phys. 81(5):e689~e695 (4.503)
2011 SCI-E Locoregional Recurrence of Breast Conserving Surgery after Preoperative Chemotherapy in Korean Women with Locally Advanced Breast Cancer: Journal of Breast Cancer. 14(4):289~295 (0.179)
2011 SCI Preoperative chemoradiation with cetuximab, irinotecan, and capecitabine in patients with locally advanced resectable rectal cancer: a multicenter phase II study: International journal of radiation oncology, biology, physics. 81:677~683 (4.503)
2011 SCI Single nucleotide polymorphisms of CYP19A1 predict clinical outcomes and adverse events associated with letrozole in patients with metastatic breast cancer: Cancer Chemotherapy and Pharmacology. 68(5):1263~1271 (2.759)
2011 SCI Social support and depressive mood 1 year after diagnosis of breast cancer compared with the general female population: a prospective cohort study.: Supportive care in cancer. 19(9):1379~1392 (2.058)
2011 SCI Adipokines, insulin resistance, metabolic syndrome, and breast cancer recurrence: a cohort study: BREAST CANCER RESEARCH. 13(2):r34~r34 (5.785)
2011 SCI Accumulation of p53 determined by immunohistochemistry as a prognostic marker in node negative breast cancer; analysis according to st gallen consensus and intrinsic subtypes.: Journal of Surgical Oncology. 103(3):207~211 (2.428)
2011 SCI Health-Related Quality of Life in Survivors With Breast Cancer 1 Year After Diagosis Compared With the General Population A Prospective Cohort Study: Annals of Surgery. 253(1):101~108 (7.474)
2010 SCI-E The invasive lobular carcinoma as a prototype luminal A breast cancer: a retrospective cohort study.: BMC cancer. 10(1):664~664 (2.736)
2010 SCI Hypomethylation of the interleukin-10 gene in breast cancer tissues: Breast. 19(6):484~488 (2.087)
2010 SCI Methylation patterns of genes coding for drug-metabolizing enzymes in tamoxifen-resistant breast cancer tissues: Journal of Molecular medicine. 88(11):1123~1131 (5.004)
2010 SCI Predictive factors of pathologic complete response and clinical tumor progression after preoperative chemotherapy in patients with stage II and III breast cancer.: Investigational new drugs. Online:Published (3.072)
2010 SCI Phase II study of gemcitabine in combination with vinorelbine versus gemcitabine followed by vinorelbine for metastatic breast cancer: Investigational New Drugs. 100(2):298~304 (3.072)
2010 SCI Concordant HER2 status between metastatic breast cancer cells in CSF and primary breast cancer tissue.: BREAST CANCER RES TR. 123(1):125~128 (4.696)
2010 SCI Phase II Parallel Group Study Showing Comparable Efficacy Between Premenopausal Metastatic Breast Cancer Patients Treated With Letrozole Plus Goserelin and Postmenopausal Patients Treated With Letrozole Alone As First-Line Hormone Therapy: Journal of Clinical Oncology. 28(16):2705~2711 (17.793)
2010 SCI Worse prognosis of metaplastic breast cancer patients than other patients with triple-negative breast cancer: Breast cancer research and treatment. 120(3):627~637 (4.696)
2010 SCI Primary systemic therapy with intermittent weekly paclitaxel plus gemcitabine in patients with stage II and III breast cancer: a phase II trial: Investigational New Drugs. 28(1):83~90 (3.072)
2010 SCI Prognostic impact of [18F] FDG-PET in operable breast cancer treated with neoadjuvant chemotherpy: Annals of Surgical Oncology. 17(1):247~253 (4.13)
2009 SCI-E Fatty fish and fish omega-3 fatty acid intakes decrease the breast cancer risk: a case-control study: BioMedCentral Cancer. 9(1):216~216 (3.087)
2009 SCI Epidermal Growth Factor Receptor Expression Discrepancies in Metastatic Colorectal Cancer Patients Treated with Cetuximab Plus Irinotecan-Based Chemotherapy Refractory to Irinotecan and Oxaliplatin: Diseases of the Colon and Rectum. 52:1144~1153 (2.615)
2009 SCI-E Potential antitumor effects of nitrogen-containing bisphosphonate in hormone receptor negative breast cancer patients with bone metastases: BMC Cancer. 9:154~154 (3.087)
2008 SCI Major response to sunitinib (Sutene(R)) in metastatic malignant phyllodes tumor of breast: Investigational New Drugs. Online:Published (2.806)
2008 SCI Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer: Annals of Oncology. Online:Published (4.875)
2008 SCI Analysis of chemotherapy-induced amenorrhea rates by three different anthracycline and taxane containing regimens for early breast cancer: Breast Cancer Research and Treatment. Online:Published (4.453)
2008 SCI Promoter hypomethylation of the N-acetyltransferase 1 gene in breast cancer: Oncology Reports. 19:663~8 (1.597)
2008 SCI Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer: Breast Cancer Research and Treatment. 108:241~250 (4.453)
2008 SCI Breast cancer subtypes and survival in patients with brain metastases: Breast Cancer Research. Online:Published (4.371)
2008 기타 A case of cutaneous acrometastasis in the right 5th finger tip by metastatic breast cancer.: The Korean Journal of Medicine. 75(1):112~114 ()
2007 SCI A randomized phase-III trial of docetaxel/capecitabine versus doxorubicin/cyclophosphamide as primary chemotherapy for patients with stage II/III breast cancer.: Breast Cancer Research and Treatment. 109:481~489 (4.671)
2007 SCI Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer: Journal of Clinical Oncology. 25:3837~3845 (15.484)
2007 SCI Assessment of clinical relevant fatigue level in cancer: Supportive Care in Cancer. 15:891~896 (1.905)
2006 SCI A phase II study with gemcitabine and split-dose cisplatin in patients with advanced non-small cell lung cancer: Lung Cancer. 54:57~62 (3.455)
2006 SCI Predicting tissue HER2 status using serum HER2 levels in patients with metastatic breast cancer: Clinical Chemistry. 52:1510~1515 (7.717)
2006 SCI-E Validation study of the Korean version of the MD andeson symptom inventory: Journal of Pain and Symptom Management. 29:165~172 (2.437)
2006 기타 Serum HER2 as a Response Indicator to Various Chemotherapeutic Agents in Tissue HER2 Positive Metastatic Breast Cancer: Cancer Research and Treatment. 38:35~39 ()
2005 기타 Randomized, multicenter phase II trial of docetaxel plus cisplatin versus etoposide plus cisplatin as the first-line therapy for patients with advanced non-small cell lung cancer: Cancer Research and Treatment. 37:332~338 ()
2005 SCI-E A Case of Primary Gastric CD30-Positive Anaplastic Large-Cell Lymphoma: Journal of Korean Medical Science. 20:1062~1065 (0.824)
2005 SCI Factors influencing preferences for place of terminal care and of death among cancer patients and their families in Korea: Suportive Care Cancer. 13:565~72 (2.122)
2005 기타 High-dose versus low-dose cyclophosphamide in combination with G-CSF for peripheral blood progenitor cell mobilization.: Korean Journal of Internal Medicine. 20:224~231 (0)
2005 기타 Clinical features of hospitalized adults with infectious mononucleosis: Korean Journal of Hematology. 40:1~7 ()
2020 SCI-E Cumulative incidence of chemotherapy-induced cardiotoxicity during a 2-year follow-up period in breast cancer patients: BREAST CANCER RESEARCH AND TREATMENT. 182(2):333~343 (3.831)
2020 SCI-E Genome-wide association study of genetic variants related to anthracycline-induced cardiotoxicity in early breast cancer: CANCER SCIENCE. Online:Published (4.966)
2020 SCI-E Phase I and pharmacokinetic study of the vascular-disrupting agent CKD-516 (NOV120401) in patients with refractory solid tumors: PHARMACOLOGY RESEARCH & PERSPECTIVES. 8(2):e00568~ (2.052)
2019 SCI Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer: THE NEW ENGLAND JOURNAL OF MEDICINE. Online:Published (70.67)
2019 SCI A pilot study on intermittent every other days of 5-dose Filgrastim compared with single Pegfilgrastim in breast Cancer patients receiving adjuvant Docetaxel, doxorubicin, and cyclophosphamide (TAC) chemotherapy: INVESTIGATIONAL NEW DRUGS. Online:Published (2.663)
2019 SCI Genomic characteristics of triple-negative breast cancer nominate molecular subtypes that predict chemotherapy response: Molecular Cancer Research. Online:Published (4.484)
2019 SCI Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2 + metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16): British journal of cancer. Online:Published (5.416)
2019 SCI Anti-tumor activity of BET inhibitors in androgen-receptor-expressing triple-negative breast cancer.: SCIENTIFIC REPORTS. Online:Published (4.011)
2019 SCI-E Anti-tumor activity of BET inhibitors in androgen-receptor-expressing triple-negative breast cancer: SCIENTIFIC REPORTS. 9(1):13305~ (3.998)
2019 SCI Molecular alterations and poziotinib efficacy, a pan-HER inhibitor, in human epidermal growth factor receptor2 (HER2)-positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2-positive breast cancer patients: INTERNATIONAL JOURNAL OF CANCER. 145(6):1669~1678 (4.982)
2019 SCI-E Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor? Positive Metastatic Breast Cancer: JAMA ONCOLOGY. Online:Published (22.416)
2019 SCI Exploratory biomarker analysis from a phase II clinical trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine for HER2-negative metastatic breast cancer patients (KCSG BR13-11): BREAST CANCER RESEARCH AND TREATMENT. 178:367~377 (3.471)
2019 SCI The Sentinel Lymph Node Biopsy Using Indocyanine Green Fluorescence Plus Radioisotope Method Compared With the Radioisotope-Only Method for Breast Cancer Patients After Neoadjuvant Chemotherapy: A Prospective, Randomized, Open-Label, Single-Center Phase 2 Trial: ANNALS OF SURGICAL ONCOLOGY. 26(8):2409~2416 (3.681)
2019 SCI Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer: THE NEW ENGLAND JOURNAL OF MEDICINE. 381(4):307~316 (70.67)
2019 SCI-E Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11): Cancer Communications. 39(1):29~29 (0)
2019 SCI-E Integrative In Vivo Drug Testing Using Gene Expression Signature and Patient-Derived Xenografts from Treatment-Refractory HER2 Positive and Triple-Negative Subtypes of Breast Cancer: CANCERS. 11(4):E574~E574 (6.162)
2019 SCI A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients: British Journal of Cancer. 120(5):475~480 (5.416)
2019 SCI PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study: British Journal of Cancer. 120(2):172~182 (5.416)
2019 SCI-E randomized open label phase III tiral of irinotecan plus capecitabine versus capecitabine monotherapy in patients with metastatic breast cancer previously treated with anthracycline and taxane : PROCEED trial (KCSG BR 11-01): CANCER RESEARCH AND TREATMENT. 51(1):43~52 (3.363)
2018 SCI-E Predicting Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer: combined Statistical Modeling Using Clinicopathological Factors and FDG PET/CT Texture Parameters: clinical nuclear medicine. 44(1):21~29 (6.309)
2018 SCI A phase II trial of the pan-HER inhibitor poziotinib, in patients with HER2-positive metastatic breast cancer who had received at least two prior HER2-directed regimens: results of the NOV120101-203 trial: INTERNATIONAL JOURNAL OF CANCER. 143(12):3240~3247 (7.36)
2018 SCI-E Magnetic Resonance Imaging (MRI) Assessment of Residual Breast Cancer After Neoadjuvant Chemotherapy: Relevance to Tumor Subtypes and MRI Interpretation Threshold.: Clinical breast cancer. 18(6):459~467 (2.703)
2018 SCI Prognostic impact of skeletal muscle volume derived from crosssectional computed tomography images in breast cancer: BREAST CANCER RESEARCH AND TREATMENT. 172(2):425~436 (3.605)
2018 SCI Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer: EUROPEAN JOURNAL OF CANCER. 103:127~136 (7.191)
2018 SCI-E Oncologic Safety of Gonadotropin-Releasing Hormone Agonist for Ovarian Function Protection During Breast Cancer Chemotherapy: Clinical breast cancer. 18(5):e1165~e1172 (2.703)
2018 SCI Use of adjuvant chemotherapy in hormone receptor-positive breast cancer patients with or without the 21-gene expression assay: Breast cancer research and treatment. 170(1):69~76 (3.605)
2018 SCI-E Phase I/II clinical trial of everolimus combined with gemcitabine/cisplatin for metastatic triple-negative breast cancer.: Journal of Cancer. 9(7):1145~1151 (3.249)
2017 SCI-E Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial.: The Lancet. Oncology. 19(1):87~100 (33.9)
2017 SCI-E Quality of life on TSU-68: Combination of docetaxel and TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer previously treated with anthracycline.: Asia-Pacific journal of clinical oncology. 13(6):365~371 (1.959)
2017 SCI Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer.: European journal of cancer. 86:385~393 (6.029)
2017 SCI-E Prognostic Impact of Elective Supraclavicular Nodal Irradiation for Patients with N1 Breast Cancer after Lumpectomy and Anthracycline plus Taxane-based Chemotherapy (KROG 1418): A Multicenter Case-Controlled Study: Cancer Research and Treatment. 49(4):970~980 (3.772)
2017 SCI-E CKAP2 (cytoskeleton-associated protein2) is a new prognostic marker in HER2-negative luminal type breast cancer: PLOS ONE. 12(8):e0182107~e0182107 (2.806)
2017 SCI Characteristics of BRCA1/2 mutations carriers including large genomic rearrangements in high risk breast cancer patients: Breast Cancer Research and Treatment. 163(1):139~150 (3.626)
2017 SCI Efficacy and safety of everolimus in combination with trastuzumab and paclitaxel in Asian patients with HER2+ advanced breast cancer in BOLERO-1.: Breast cancer research. 19(1):47~47 (6.345)
2016 SCI-E Post-mastectomy Radiotherapy in Patients with pT1-2N1 Breast Cancer Treated with Taxane-based Chemotherapy: A Retrospective Multicenter Analysis (KROG 1418).: Cancer Research and Treatment. Online:Published (4.245)
2016 SCI-E Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results: Cancer Research and treatment. 49(2):423~429 (4.245)
2016 SCI-E Optimal radiation dose for patients with one to three lymph node positive breast cancer following breast-conserving surgery and anthracycline plus taxane-based chemotherapy: A retrospective multicenter analysis (KROG 1418): Oncotarget. 8(1):1796~1804 (5.008)
2016 SCI-E Accelerated whole breast irradiation in early breast cancer patients with adverse prognostic features.: Oncotarget. 7(49):81888~81898 (5.008)
2016 SSCI Three-Year Prospective Cohort Study of Factors Associated with Return to Work After Breast Cancer Diagnosis.: Journal of Occup Rehabilitation. Online:Published (1.644)
2016 SCI-E Effects of Postoperative Radiotherapy on Leptomeningeal Carcinomatosis or Dural Metastasis After Resection of Brain Metastases in Breast Cancer Patients: Cancer Research and Treatment. Online:Published (4.245)
2016 SCI-E The Significance of Serum HER2 Levels at Diagnosis on Intrinsic Subtype-Specific Outcome of Operable Breast Cancer Patients: PLOS ONE. 11(10):e0163370~e0163370 (3.057)
2016 SCI-E Locoregional Recurrence by Tumor Biology in Breast Cancer Patients after Preoperative Chemotherapy and Breast Conservation Treatment: Cancer research and treatment. 48(4):1363~1372 (4.245)
2016 SCI-E Prognostic Value of Axillary Nodal Ratio after Neoadjuvant Chemotherapy of Doxorubicin/Cyclophosphamide Followed by Docetaxel: A Multicenter Retrospective Cohort Study: Cancer Res Treatment. 48(4):1373~1381 (4.245)
2016 SCI-E An open label randomized parallel phase III trial evaluating the efficacy and safety of polymeric micelle formulated paclitaxel compared to conventional cremophor EL-based paclitaxel for recurrent or metastatic HER2 negative breast cancer: cancer research and treatment. Online:Published (4.245)
2016 SCI-E A Rare Case of Phyllodes Tumor Metastasis to the Stomach Presenting as Anemia: Cancer research and treatment. Online:Published (4.245)
2016 SCI A Comparative Study of Daily 3-Gy Hypofractionated and 1.8-Gy Conventional Breast Irradiation in Early-Stage Breast Cancer: Medicine. 95(19):e3320~e3320 (2.133)
2016 SCI Identifying the potential long-term survivors among breast cancer patients with distant metastasis: Annals of oncology. 27(5):828~833 (9.269)
2015 SCI-E Effect of Time Interval between Breast-conserving Surgery and Radiation Therapy on Outcomes of Node-positive Breast Cancer Patients Treated with Adjuvant Doxorubicin/Cyclophosphamide followed by Taxane: Cancer research and treatment. 48(2):483~490 (3.318)
2015 SCI-E Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer: Clinical Breast Cancer. 16(1):51~58 (2.107)
2015 SCI-E Impact of Molecular Subtype Conversion of Breast Cancers after Neoadjuvant Chemotherapy on Clinical Outcome: Cancer research and treatment. 48(1):133~141 (3.318)
2015 SSCI Changes in health-related quality of life and quality of care among terminally ill cancer patients and survival prediction: Multicenter prospective cohort study: Palliative & supportive care. 13(4):1103~1111 (1.525)
2015 SCI-E Breast Cancer-Related Lymphedema after Neoadjuvant Chemotherapy: Cancer research and treatment. 47(3):416~423 (3.318)
2015 SCI-E Effects of Second and Subsequent Lines of Chemotherapy for Metastatic Breast Cancer: Clinical breast cancer. 15(1):e55~e62 (2.107)
2014 SCI-E Outcomes of palliative weekly low-dose gemcitabine-Cisplatin chemotherapy in anthracycline- and taxane- pretreated metastatic breast cancer patients: Journal of breast cancer. 17(4):339~343 (1.317)
2014 SCI High Volumetric Breast Density Predicts Risk for Breast Cancer in Postmenopausal, but not Premenopausal, Korean Women: Annals of surgical oncology. 21(13):4124~4132 (3.943)
2014 SCI Identification and clinical implications of circulating microRNAs for estrogen receptor-positive breast cancer.: Tumor biology. 35(12):12173~12180 (2.84)
2014 SCI Treatment factors affecting breast cancer-related lymphedema after systemic chemotherapy and radiotherapy in stage II/III breast cancer patients: Breast cancer research and treatment. 148(1):91~98 (4.198)
2014 SCI Comparison of Sentinel Lymph Node Biopsy Guided by the Multimodal Method of Indocyanine Green Fluorescence, Radioisotope, and Blue Dye Versus the Radioisotope Method in Breast Cancer: A Randomized Controlled Trial: Annals of Surgical Oncology. 21(4):1254~1259 (3.943)
2014 SCI-E Association of Polymorphisms and Haplotypes in the Insulin-Like Growth Factor 1 Receptor (IGF1R) Gene with the Risk of Breast Cancer in Korean Women.: PLOS One. 9(1):e84532~e84532 (3.534)
2013 SCI Phase 2 trial of accelerated, hypofractionated whole-breast irradiation of 39 Gy in 13 fractions followed by a tumor bed boost sequentially delivering 9 Gy in 3 fractions in early-stage breast cancer: International Journal of Radiation Oncology Biology Physics. 87(5):1037~1042 (4.524)
2013 SCI-E Burdens, Needs and Satisfaction of Terminal Cancer Patients and their Caregivers: Asian Pacific Journal of Cancer Prevention. 14(1):209~216 (1.271)
2013 SCI Phase III, Multicenter, Randomized Trial of Maintenance Chemotherapy Versus Observation in Patients With Metastatistic Breast Cancer After Achieving Disease Control With Six Cycles of Gemcitabine Plus Paclitaxel As First-Line Chemotherapy: KCSG-BR07-02: Journal of Clinical Oncology. 31(4):1732~1739 (18.038)
2013 SCI Phase II study of irinotecan plus capecitabine in anthracycline- and taxane- pretreated patients with metastatic breast cancer: Investigational new drugs. 31(1):152~159 (3.498)
2013 SCI Effect of complementary and alternative medicine on the survival and health-related quality of life among terminally ill cancer patients: a prospective cohort study.: Annals of Oncology. 24(2):489~494 (7.384)
2013 SCI-E A Case of Locally Advanced Breast Cancer Complicated by Pulmonary Tumor Thrombotic Microangiopathy: Cancer Research and Treatment. 44(4):267~270 (0)
2012 SCI-E Percutaneous radiofrequency ablation for liver metastases in breast cancer patients: The Breast Journal. 19(5):563~565 (1.831)
2012 SCI-E Stage-to-stage Comparison of Neoadjuvant Chemotherapy Versus Adjuvant Chemotherapy in Pathological Lymph Node Positive Breast Cancer Patients: Japanese Journal of Clinical Oncology. 42(11):995~1001 (1.783)
2012 SCI Resumption or persistence of menstruation after cytotoxic chemotherapy is a prognostic factor for poor disease-free survival in premenopausal patients with early breast cancer: Annals of Oncology. 23(9):2283~2289 (6.425)
2012 SCI-E Efficacy of Exemestane after Nonsteroidal Aromatase Inhibitor Use in Metastatic Breast Cancer Patients: Asian Pacific journal of cancer prevention. 13(3):979~983 (0.659)
2012 SCI-E Correlation of HER2 p95HER2 and HER3 expression and treatment outcome of lapatinib plus capecitabine in her2-Positive Metastatic Breast Cancer: PLOS ONE. 7(7):e39943~e39943 (4.092)
2012 SCI Metaplastic breast cancer: clinicopathological features and its prognosis: Journal of clinical pathology. 65(5):441~446 (2.306)
2012 SCI Web-Based Tailored Education Program for Disease-Free Cancer Survivors With Cancer-Related Fatigue: A Randomized Controlled Trial: Journal of Clinical Oncology. 30(12):1296~1303 (18.372)
2012 SCI Phase II trial of preoperative paclitaxel, gemcitabine, and trastuzumab combination therapy in HER2 positive stage II/III breast cancer: The Korean Cancer Study Group BR 07-01: Breast Cancer Res Treat. 132(2):589~600 (4.431)
2012 SCI lack of any association between functionally significant CYP2D6 polymorphisms and clinical outcomes in early breast cancer patients receiving adjuvant tamoxifen treatment: Breast cancer research and treatment. 131(2):455~461 (4.431)
2012 SCI High serum TGF-a predicts poor response to lapatinib and capecitabine in HER2-positive breast cancer: Breast Cancer Research and Treatment. 125(1):107~114 (4.859)
2011 SCI A phase Ib study of preoperative lapatinib, paclitaxel, and gemcitabine combination therapy in women with HER2 positive early breast cancer: Investigational New Drugs. 30(5):1972~1977 (3.357)
2011 SCI Use of a Decision Aid to Help Caregivers Discuss Terminal Disease Status With a Family Member With Cancer: A Randomized Controlled Trial.: Journal of Clinical Oncology. 29(36):4811~4819 (18.97)
2011 SCI Locoregional recurrence of breast cancer in patients treated with breast conservation surgery and radiotherapy following neoadjuvant chemotherapy.: International Journal of Radiation Oncology*Biology*Physics. 81(5):e697~e705 (4.503)
2011 SCI Outcomes of Positron Emission Tomography-Staged Clinical N3 Breast Cancer Treated with Neoadjuvant Chemotherapy, Surgery, and Radiotherapy.: Int J Radiat Oncol Biol Phys. 81(5):e689~e695 (4.503)
2011 SCI-E Locoregional Recurrence of Breast Conserving Surgery after Preoperative Chemotherapy in Korean Women with Locally Advanced Breast Cancer: Journal of Breast Cancer. 14(4):289~295 (0.179)
2011 SCI Preoperative chemoradiation with cetuximab, irinotecan, and capecitabine in patients with locally advanced resectable rectal cancer: a multicenter phase II study: International journal of radiation oncology, biology, physics. 81:677~683 (4.503)
2011 SCI Single nucleotide polymorphisms of CYP19A1 predict clinical outcomes and adverse events associated with letrozole in patients with metastatic breast cancer: Cancer Chemotherapy and Pharmacology. 68(5):1263~1271 (2.759)
2011 SCI Social support and depressive mood 1 year after diagnosis of breast cancer compared with the general female population: a prospective cohort study.: Supportive care in cancer. 19(9):1379~1392 (2.058)
2011 SCI Adipokines, insulin resistance, metabolic syndrome, and breast cancer recurrence: a cohort study: BREAST CANCER RESEARCH. 13(2):r34~r34 (5.785)
2011 SCI Accumulation of p53 determined by immunohistochemistry as a prognostic marker in node negative breast cancer; analysis according to st gallen consensus and intrinsic subtypes.: Journal of Surgical Oncology. 103(3):207~211 (2.428)
2011 SCI Health-Related Quality of Life in Survivors With Breast Cancer 1 Year After Diagosis Compared With the General Population A Prospective Cohort Study: Annals of Surgery. 253(1):101~108 (7.474)
2010 SCI-E The invasive lobular carcinoma as a prototype luminal A breast cancer: a retrospective cohort study.: BMC cancer. 10(1):664~664 (2.736)
2010 SCI Hypomethylation of the interleukin-10 gene in breast cancer tissues: Breast. 19(6):484~488 (2.087)
2010 SCI Methylation patterns of genes coding for drug-metabolizing enzymes in tamoxifen-resistant breast cancer tissues: Journal of Molecular medicine. 88(11):1123~1131 (5.004)
2010 SCI Predictive factors of pathologic complete response and clinical tumor progression after preoperative chemotherapy in patients with stage II and III breast cancer.: Investigational new drugs. Online:Published (3.072)
2010 SCI Phase II study of gemcitabine in combination with vinorelbine versus gemcitabine followed by vinorelbine for metastatic breast cancer: Investigational New Drugs. 100(2):298~304 (3.072)
2010 SCI Concordant HER2 status between metastatic breast cancer cells in CSF and primary breast cancer tissue.: BREAST CANCER RES TR. 123(1):125~128 (4.696)
2010 SCI Phase II Parallel Group Study Showing Comparable Efficacy Between Premenopausal Metastatic Breast Cancer Patients Treated With Letrozole Plus Goserelin and Postmenopausal Patients Treated With Letrozole Alone As First-Line Hormone Therapy: Journal of Clinical Oncology. 28(16):2705~2711 (17.793)
2010 SCI Worse prognosis of metaplastic breast cancer patients than other patients with triple-negative breast cancer: Breast cancer research and treatment. 120(3):627~637 (4.696)
2010 SCI Primary systemic therapy with intermittent weekly paclitaxel plus gemcitabine in patients with stage II and III breast cancer: a phase II trial: Investigational New Drugs. 28(1):83~90 (3.072)
2010 SCI Prognostic impact of [18F] FDG-PET in operable breast cancer treated with neoadjuvant chemotherpy: Annals of Surgical Oncology. 17(1):247~253 (4.13)
2009 SCI-E Fatty fish and fish omega-3 fatty acid intakes decrease the breast cancer risk: a case-control study: BioMedCentral Cancer. 9(1):216~216 (3.087)
2009 SCI Epidermal Growth Factor Receptor Expression Discrepancies in Metastatic Colorectal Cancer Patients Treated with Cetuximab Plus Irinotecan-Based Chemotherapy Refractory to Irinotecan and Oxaliplatin: Diseases of the Colon and Rectum. 52:1144~1153 (2.615)
2009 SCI-E Potential antitumor effects of nitrogen-containing bisphosphonate in hormone receptor negative breast cancer patients with bone metastases: BMC Cancer. 9:154~154 (3.087)
2008 SCI Major response to sunitinib (Sutene(R)) in metastatic malignant phyllodes tumor of breast: Investigational New Drugs. Online:Published (2.806)
2008 SCI Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer: Annals of Oncology. Online:Published (4.875)
2008 SCI Analysis of chemotherapy-induced amenorrhea rates by three different anthracycline and taxane containing regimens for early breast cancer: Breast Cancer Research and Treatment. Online:Published (4.453)
2008 SCI Promoter hypomethylation of the N-acetyltransferase 1 gene in breast cancer: Oncology Reports. 19:663~8 (1.597)
2008 SCI Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer: Breast Cancer Research and Treatment. 108:241~250 (4.453)
2008 SCI Breast cancer subtypes and survival in patients with brain metastases: Breast Cancer Research. Online:Published (4.371)
2008 기타 A case of cutaneous acrometastasis in the right 5th finger tip by metastatic breast cancer.: The Korean Journal of Medicine. 75(1):112~114 ()
2007 SCI A randomized phase-III trial of docetaxel/capecitabine versus doxorubicin/cyclophosphamide as primary chemotherapy for patients with stage II/III breast cancer.: Breast Cancer Research and Treatment. 109:481~489 (4.671)
2007 SCI Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer: Journal of Clinical Oncology. 25:3837~3845 (15.484)
2007 SCI Assessment of clinical relevant fatigue level in cancer: Supportive Care in Cancer. 15:891~896 (1.905)
2006 SCI A phase II study with gemcitabine and split-dose cisplatin in patients with advanced non-small cell lung cancer: Lung Cancer. 54:57~62 (3.455)
2006 SCI Predicting tissue HER2 status using serum HER2 levels in patients with metastatic breast cancer: Clinical Chemistry. 52:1510~1515 (7.717)
2006 SCI-E Validation study of the Korean version of the MD andeson symptom inventory: Journal of Pain and Symptom Management. 29:165~172 (2.437)
2006 기타 Serum HER2 as a Response Indicator to Various Chemotherapeutic Agents in Tissue HER2 Positive Metastatic Breast Cancer: Cancer Research and Treatment. 38:35~39 ()
2005 기타 Randomized, multicenter phase II trial of docetaxel plus cisplatin versus etoposide plus cisplatin as the first-line therapy for patients with advanced non-small cell lung cancer: Cancer Research and Treatment. 37:332~338 ()
2005 SCI-E A Case of Primary Gastric CD30-Positive Anaplastic Large-Cell Lymphoma: Journal of Korean Medical Science. 20:1062~1065 (0.824)
2005 SCI Factors influencing preferences for place of terminal care and of death among cancer patients and their families in Korea: Suportive Care Cancer. 13:565~72 (2.122)
2005 기타 High-dose versus low-dose cyclophosphamide in combination with G-CSF for peripheral blood progenitor cell mobilization.: Korean Journal of Internal Medicine. 20:224~231 (0)
2005 기타 Clinical features of hospitalized adults with infectious mononucleosis: Korean Journal of Hematology. 40:1~7 ()
저서
2005 암진료 가이드 일조각
2005 완화의학 군자출판사
2005 완화의학 군자출판사
보도자료
허셉틴 유방암 환자에게 희망을 주는 의약품입니다
http://www.bosa.co.kr/news/articleView.html?idxno=2136041
"버제니오 급여, 유방암환자에 큰 선물"
http://www.dailymedi.com/detail.php?number=856785&thread=22r05
[암환자 의사를 만나다] 일·가정 책임에 투병까지...'마음 고생' 젊은 유방암
http://www.kukinews.com/newsView/kuk201911110295
[암, 지피지기면 백전백승] (9)유방암 여성암 발병률 2위…가슴 쪽 멍울 만져지면 병원 찾아야
https://www.nongmin.com/plan/PLN/SRS/284179/view
[최신 암 치료법] 항암치료·일상생활 병행 가능한 시대
https://www.hankyung.com/society/article/2013112621651
유방암의 다양한 얼굴…‘삼중음성유방암’ 아시나요
http://news.khan.co.kr/kh_news/khan_art_view.html?artid=202010291508002&code=900303
http://www.bosa.co.kr/news/articleView.html?idxno=2136041
"버제니오 급여, 유방암환자에 큰 선물"
http://www.dailymedi.com/detail.php?number=856785&thread=22r05
[암환자 의사를 만나다] 일·가정 책임에 투병까지...'마음 고생' 젊은 유방암
http://www.kukinews.com/newsView/kuk201911110295
[암, 지피지기면 백전백승] (9)유방암 여성암 발병률 2위…가슴 쪽 멍울 만져지면 병원 찾아야
https://www.nongmin.com/plan/PLN/SRS/284179/view
[최신 암 치료법] 항암치료·일상생활 병행 가능한 시대
https://www.hankyung.com/society/article/2013112621651
유방암의 다양한 얼굴…‘삼중음성유방암’ 아시나요
http://news.khan.co.kr/kh_news/khan_art_view.html?artid=202010291508002&code=900303
포스팅
포스팅 내용이 없습니다.
영상자료
10년 새 유방암 · 전립선암 증가…부족한 잠도 원인
https://news.sbs.co.kr/news/endPage.do?news_id=N1005577778&plink=ORI&cooper=NAVER&plink=COPYPASTE&cooper=SBSNEWSEND
https://news.sbs.co.kr/news/endPage.do?news_id=N1005577778&plink=ORI&cooper=NAVER&plink=COPYPASTE&cooper=SBSNEWSEND
발표자료
발표자료 내용이 없습니다.